Stock MEIP MEI PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
3.31 USD +3.44% Intraday chart for MEI Pharma, Inc. -11.97% -42.93%
Apr. 11 MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data CI
Apr. 11 MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients CI

Evolution of the average Target Price on MEI Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4f.oVvKLPjT0RqpB88ZqTRQX4Rvl1M711drR50TrC4Z1cs.-y2CeZqHs1XwRq0gwnkAPvMl3WN3mRheJq1AgX5arIXKNPplmbe1feZvpA~4a7ab9f267eeaf63c489e21bc4f1302b

Analyst Recommendations on MEI Pharma, Inc.

Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating MT
Stifel Adjusts Price Target on MEI Pharma to $9 From $10, Maintains Hold Rating MT
Stifel Adjusts MEI Pharma's Price Target to $10 From $0.50, Keeps Hold Rating MT
Stifel Nicolaus Adjusts MEI Pharma Price Target to $0.50 From $2, Maintains Hold Rating MT
HC Wainwright Adjusts Price Target on MEI Pharma to $2 From $5, Maintains Buy Rating MT
Jefferies Downgrades MEI Pharma to Underperform From Hold, Adjusts Price Target to $0.10 From $0.40 MT
BTIG Downgrades MEI Pharma to Neutral From Buy MT
Truist Securities Downgrades MEI Pharma to Hold From Buy MT
Brookline Capital Markets Adjusts MEI Pharma Price Target to $15 From $20, Maintains Buy Rating MT
BTIG Adjusts MEI Pharma's Price Target to $4 From $11, Reiterates Buy Rating MT
Truist Securities Adjusts MEI Pharma's Price Target to $3 From $8, Reiterates Buy Rating MT
Wells Fargo Downgrades MEI Pharma to Equalweight From Overweight, Adjusts Price Target to $2 From $13 MT
HC Wainwright Adjusts MEI Pharma's Price Target to $5 From $10, Reiterates Buy Rating MT
Stifel Lowers MEI Pharma to Hold From Buy, Price Target to $2 From $6 MT
Jefferies Cuts MEI Pharma to Hold From Buy, Price Target to $1 From $4 MT
Jefferies Starts MEI Pharma at Buy With $4 Price Target MT
MEI Pharma Says Treatment With Follicular Lymphoma Drug Candidate Shows Complete Response Rate of Over 35% in Mid-Stage Trial MT
MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of Me-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.31 USD
Average target price
23 USD
Spread / Average Target
+594.86%
High Price Target
42 USD
Spread / Highest target
+1,168.88%
Low Price Target
7 USD
Spread / Lowest Target
+111.48%

Consensus detail

Consensus revision (last 18 months)

Analysts covering MEI Pharma, Inc.

Stifel Nicolaus
HC Wainwright
Jefferies & Co.
Truist Securities
BTIG
Wells Fargo Securities
Brookline Capital Markets

Ratings for MEI Pharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MEIP Stock
  4. Consensus MEI Pharma, Inc.